InvestorsObserver
Sign Up Login

NBSE Neu Base Therapeutics Inc

$0.44 $0.00 (-0.55%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

NBSE Stock Analysis Overview

What this means: Neu Base Therapeutics Inc (NBSE) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives NBSE a rank of 3. Our methodology considers analysis of the company's financial situation and how it has traded recently. NBSE rank of 3 means that it ranks below 97% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

NBSE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

NBSE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

NBSE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

NBSE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

NBSE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

NBSE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

NBSE Stock Analysis Overview

What this means: Neu Base Therapeutics Inc (NBSE) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives NBSE a rank of 3. Our methodology considers analysis of the company's financial situation and how it has traded recently. NBSE rank of 3 means that it ranks below 97% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full NBSE report

NBSE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

NBSE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

NBSE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

NBSE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

NBSE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

NBSE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Neu Base Therapeutics Inc (NBSE) Analyst Forecast

NBSE Price, Volume, Earnings, and Dividend Date

  • Last Price $0.44
  • Previous Close $0.44
  • Change $0.00
  • Open $0.43
  • Volume 69,551
  • Avg. Volume (100-day) 212,815
  • Market Cap 1,648,309
  • Days Range 0.412 - 0.45
  • 52-week Range 0.39 - 4.8
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 05/09/24
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta -0.776
  • PEG Ratio —

Neu Base Therapeutics Inc (NBSE) Company Description

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

Neu Base Therapeutics Inc (NBSE) Stock Chart

View Interactive NBSE chart

My Watchlists

Top Stocks in Biotechnology